|Bid||40.54 x 800|
|Ask||40.55 x 2900|
|Day's Range||40.50 - 40.85|
|52 Week Range||39.23 - 56.32|
|Beta (5Y Monthly)||0.58|
|PE Ratio (TTM)||23.76|
|Earnings Date||May 01, 2023 - May 05, 2023|
|Forward Dividend & Yield||1.64 (3.76%)|
|Ex-Dividend Date||Jan 26, 2023|
|1y Target Est||52.81|
Moderna CEO Stéphane Bancel is set to face Sen. Bernie Sanders to defend the company's fast growth and planned price hike of its COVID-19 vaccine.
The U.S. government will not force Pfizer Inc and Astellas Pharma Inc to lower the price of their prostate cancer drug Xtandi using its emergency "march-in" authority, the National Institutes of Health (NIH) said on Tuesday. Xtandi's wholesale cost is between $160,000-$180,000 per patient a year. Patient group the Union for Affordable Cancer Treatment first filed a petition calling on the NIH to use its authority to lower the drug's price in March 2016.
NEW YORK, March 21, 2023--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 2, 2023. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2023 Performance Report, to be issued that morning.